Vyndaqel  (tafamidis meglumine) –  To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.

Box of Vyndaqel

VYNDAQEL DOSAGE AND ADMINISTRATION 

The recommended dosage is either:
• VYNDAQEL 80 mg orally once daily, or
• VYNDAMAX 61 mg orally once daily
• VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis.

 

VYNDAQEL INDICATIONS AND USAGE

VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild type or hereditary
transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

 

VYNDAQEL DOSAGE FORMS AND STRENGTHS 

Capsules: Tafamidis meglumine 20 mg and tafamidis 61 mg.

 

VYNDAQEL USE IN SPECIFIC POPULATIONS 

• Pregnancy: Based on animal studies, may cause fetal harm.
• Lactation: Advise not to breastfeed.